The cheapest tirzepatide in 2026 starts at $125 a month.
That's compounded tirzepatide from a 503A telehealth pharmacy. The cheapest FDA-approved option is a Zepbound vial through LillyDirect at $299 per month. Brand-name Mounjaro and Zepbound still retail between $1,000 and $1,400 a month without insurance, but almost nobody actually pays that anymore. Here's exactly where the floor sits, what you give up at each price tier, and the red flags that turn a cheap headline into an expensive mistake.
Real GLP-1 before and after results
Four real before-and-after photos from users online who shared their GLP-1 results. Identifiers blurred for privacy. Click any photo to expand.
Photos sourced from users online who publicly shared their GLP-1 results. All four used compounded semaglutide or tirzepatide, the same medications available through MEDVi and Yucca Health telehealth. Individual results vary; trial average is 15-20% body weight loss at 60+ weeks.
🔑 Key Takeaways
- Compounded tirzepatide from a 503A pharmacy via telehealth runs $125 to $399 per month, with Trimi and GobyMeds anchoring the floor.
- LillyDirect Self Pay sells Zepbound vials at $299 (2.5 mg), $399 (5 mg), and $449 (7.5 to 15 mg), the cheapest FDA-approved cash price for tirzepatide.
- The Mounjaro and Zepbound savings cards drop monthly cost to $25 if you have commercial insurance and a qualifying diagnosis (T2D for Mounjaro, obesity for Zepbound).
- FDA enforcement on compounded tirzepatide tightened on March 5, 2025; reputable pharmacies now require a "personalized" formulation justification, often a B12 additive.
- Hidden fees, dose-tier price jumps at 7.5 mg, and 6 to 12 month prepayment lock-ins can add 30% to 60% to a quoted "starting at" price.
Telehealth Comparison Table
If you'd rather skip the research-vial route, here are the two telehealth providers our readers use most for compounded semaglutide and tirzepatide.
Cheapest Tirzepatide Options in 2026, Ranked
Pricing reset twice in the last year: the FDA ended the tirzepatide shortage in late 2024, and Eli Lilly launched LillyDirect single-dose vial pricing that crushed the brand cash market. Here's what the floor looks like now.
| Option | Form | Monthly cost | FDA-approved | Best for |
|---|---|---|---|---|
| Compounded tirzepatide (Trimi) | Injection | $125 | No (503A) | Absolute cheapest |
| Compounded tirzepatide (Henry Meds, Eden, Peak) | Injection | $229 to $349 | No (503A) | Established providers |
| Compounded tirzepatide oral/troche | Tablet/lozenge | $279 to $399 | No (503A) | Needle-averse |
| Zepbound vials (LillyDirect) | Vial + syringe | $299 to $449 | Yes | Cheapest FDA-approved |
| Mounjaro / Zepbound savings card | Pen injector | $25 | Yes | Commercial insurance |
| Brand Mounjaro / Zepbound retail | Pen injector | $1,000 to $1,400 | Yes | Last resort cash |
1. Compounded Tirzepatide: $125 to $399 per Month
Compounded tirzepatide is what every cheap-tirzepatide article points to first. The legal landscape narrowed when the FDA ended the shortage in late 2024 and finished its enforcement grace period on March 5, 2025. Compounded tirzepatide is still legal under 503A rules, but the formulation must be "personalized" for the patient, usually with a small added ingredient like B12 or a specific dosing strength not commercially available.
The cheapest verified providers as of May 2026:
Lowest-cost compounded tirzepatide telehealth providers
- Trimi: $125 per month, all-in, with B12 personalization
- GobyMeds: $119 to $179 per month (limited dose tiers)
- ReflexMD: starting $92 per month at intro dose
- Peak Wellness: $229 first month / $349 ongoing, or $1,396 for 6 months ($232 per month)
- Eden Health: $299 first month / $349 ongoing
- Henry Meds: $299 to $349 per month, $234 if prepaid annually
- MyStart Health: $299 per month all-inclusive
- Hims/Hers: $199 to $299 per month
- Mochi Health: $208 per month all-in
- Shed (ShedRx): $299 to $399 (jumps at 7.5 mg)
- Willow: $399 per month (32 states)
Honest tradeoff: compounded tirzepatide is not FDA-approved as a finished injectable. The active molecule is identical to what's in Mounjaro and Zepbound. The compounding pharmacy is state-licensed and federally regulated. What you give up is the FDA's review of the finished formulation and the manufacturer's quality-control chain. For most healthy adults that's an acceptable trade for an 80% to 90% price reduction. For pregnant women, anyone with a thyroid cancer history, or anyone with severe pancreatitis risk, it isn't.
2. LillyDirect Zepbound Vials: $299, $399, $449
This is the price that broke the brand cash-pay market. Eli Lilly began selling single-dose Zepbound vials directly to consumers in 2024, at prices that beat almost every compounding pharmacy's "all-inclusive" rate once you add membership fees and labs.
| Zepbound vial dose | LillyDirect cash price | Annual cost |
|---|---|---|
| 2.5 mg (starting dose) | $299 per month | $3,588 |
| 5 mg | $399 per month | $4,788 |
| 7.5 mg | $449 per month | $5,388 |
| 10 mg | $449 per month | $5,388 |
| 12.5 mg | $449 per month | $5,388 |
| 15 mg | $449 per month | $5,388 |
You get a vial and draw the dose with a separate syringe. That's the only friction. The active drug is identical to the auto-injector pen. To stay in the program you have to refill within 45 days; gaps reset the pricing tier.
For anyone who wants FDA-approved tirzepatide and is comfortable with a vial-and-syringe workflow, this is the cheapest legal path that carries the manufacturer label.
How to Get the Cheapest Tirzepatide: Step by Step
Use this numbered protocol to land the lowest legitimate price for your situation, whether you have insurance or not.
- Check your insurance for a GLP-1 benefit. Call the number on your card and ask if Mounjaro (Type 2 diabetes) or Zepbound (weight management) is on formulary. If yes, the $25 savings card is your cheapest route.
- If covered, download the savings card. Get the Mounjaro card at Mounjaro.com or the Zepbound card at Zepbound.com, then present it at the pharmacy with your prescription. The copay drops to $25 per month up to a $1,950 annual cap.
- If excluded or uninsured, compare LillyDirect vials. Order Zepbound single-dose vials direct from Eli Lilly at $299 (2.5 mg), $399 (5 mg), or $449 (7.5 mg and up). This is the cheapest FDA-approved cash price for tirzepatide.
- Or choose a 503A telehealth pharmacy for compounded tirzepatide. Complete an online medical intake, get a prescriber evaluation, and receive compounded tirzepatide for $125 to $399 per month. Confirm the pharmacy is named, licensed, and will share a Certificate of Analysis.
- Add up the true monthly cost. Factor in membership fees ($20 to $50), labs ($50 to $200 per quarter), shipping, and the dose-tier jump that usually hits at 7.5 mg. The cheapest "starting at" headline rarely matches month two.
- Pay with HSA or FSA dollars if you have them. Tirzepatide prescribed for a qualifying condition is an eligible expense, cutting your effective cost 22% to 37% depending on your tax bracket.
- Lock in titration, not just price. Whichever route you pick, stay on a steady dose schedule. Consistency drives results far more than which legal source filled the vial.
3. Mounjaro and Zepbound Savings Cards: $25 per Month
If you have commercial insurance (employer plan or marketplace, not Medicare or Medicaid), the savings card route is the cheapest way to get brand-name tirzepatide. The path is different for the two indications.
Mounjaro savings card ($25/month)
- Requires Type 2 diabetes diagnosis
- Requires commercial insurance that covers Mounjaro for T2D
- Annual savings cap: $1,950
- Apply at Mounjaro.com, present at pharmacy
Zepbound savings card ($25/month)
- Requires obesity diagnosis (BMI 30+, or 27+ with comorbidity)
- Requires commercial insurance that covers Zepbound for weight management
- Annual savings cap: $1,950
- Apply at Zepbound.com, present at pharmacy
If your insurance plan has a GLP-1 weight-loss exclusion, the savings card alone won't bridge the gap and you'll fall back to the LillyDirect vial price or compounded.
4. Compounded Tirzepatide Oral and Troche: $279 to $399
For people who genuinely won't inject, several telehealth platforms now offer compounded tirzepatide as an oral tablet, sublingual troche, or liquid drop. Pricing tracks the injectable cost, sometimes slightly higher because the formulation is more specialized.
- MEDVi: compounded tirzepatide tablet $279 first month, $399 ongoing
- OnlineSemaglutide.org: tirzepatide drop $399 per month
- Shed: sublingual tirzepatide $349 to $499
The bioavailability of oral tirzepatide is meaningfully lower than injection (the molecule is a peptide and is partly degraded in the gut). For comparable weight-loss results, the dose has to be higher, which means the cost-per-effective-milligram is usually worse than the injectable form. The use case is needle aversion, not cost savings.
12-Month Total Cost of Tirzepatide in 2026
Monthly headlines hide the real number. Here is what a full year of tirzepatide actually costs across every legal path, assuming a typical titration to a mid-range maintenance dose. Compounded and savings-card figures exclude consult and lab add-ons.
| Path | Typical monthly cost | 12-month total | FDA-approved |
|---|---|---|---|
| Compounded tirzepatide (floor, Trimi/ReflexMD) | $125/mo | $1,500 | No (503A) |
| Compounded tirzepatide (established providers) | $229 to $349/mo | $2,748 to $4,188 | No (503A) |
| Zepbound vials via LillyDirect (5 mg maintenance) | $399/mo | $4,788 | Yes |
| Zepbound vials via LillyDirect (7.5 mg+ maintenance) | $449/mo | $5,388 | Yes |
| Mounjaro / Zepbound savings card (commercial insurance) | $25/mo | $300 (capped at $1,950 savings) | Yes |
| Brand Mounjaro / Zepbound retail (no insurance, no program) | $1,000 to $1,400/mo | $12,000 to $16,800 | Yes |
The gap between the cheapest legal floor and full retail is roughly 10 times over a year. For most uninsured patients the practical decision is between the $1,500 compounded floor and the $4,788 FDA-approved LillyDirect vial path. Compare these against semaglutide options in our cheapest GLP-1 in 2026 guide and the broader GLP-1 without insurance cost options breakdown.
Why Tirzepatide Is the Most Effective GLP-1, Ranked Against Cost
Tirzepatide consistently outperforms semaglutide in head-to-head data. The SURMOUNT-1 trial showed 20.9% average body-weight reduction at the 15 mg dose over 72 weeks. Semaglutide (STEP-1) showed 14.9% over a similar period. That difference is large enough that even at a higher monthly cost, tirzepatide can be the better cost-per-pound-lost option.
| Drug | Avg. weight loss (trial) | Cheapest legal monthly cost | Cost per % body weight lost (rough) |
|---|---|---|---|
| Tirzepatide (compounded) | 20.9% | $125 to $349 | ~$430 to $1,200 per percentage point |
| Semaglutide (compounded) | 14.9% | $99 to $249 | ~$480 to $1,200 per percentage point |
| Liraglutide (compounded) | ~8% | $99 to $149 | ~$745 to $1,120 per percentage point |
For a deeper head-to-head comparison see our guide on weight loss peptides compared and the GLP-1 side effects breakdown.
State-by-State Pricing Variation at Local Clinics
Telehealth prices are roughly the same nationwide. In-person clinic prices vary wildly by state. Local clinic monthly costs for tirzepatide we've tracked:
- Texas, Florida, Arizona, Georgia, Tennessee: $400 to $500 per month
- California, New York, Massachusetts, Washington: $550 to $725 per month
- Mid-South and Midwest states: $425 to $550 per month
If telehealth works for you, ignore this. If you need an in-person clinic for any reason, expect to pay 2 to 4 times the cheapest telehealth price.
Hidden Costs That Inflate the Headline Price
The "$125 a month" headline almost never lands at $125. Here's what to actually budget for:
Add-on costs to factor in
- Membership fees: $20 to $50 per month on top of medication (Mochi, Hims, Ro, Noom)
- Lab work: $50 to $200 every 3 to 6 months (some platforms include)
- Shipping: $15 to $30 per refill if not free
- Dose-tier jumps: Most platforms raise prices 20% to 50% at 7.5 mg+
- Initial consultation: $19 to $129 one-time
- Auto-renewal lock-in: Lowest prices typically require 6 or 12 month prepay
- LillyDirect 45-day refill rule: miss the window and pricing resets
Compounded vs Brand: How to Decide
Choose compounded tirzepatide if
- You don't have insurance, or your insurance excludes GLP-1 weight-loss coverage.
- You want to start within a week.
- You've reviewed the contraindications and have no thyroid cancer history, no severe pancreatitis history, and aren't pregnant or planning pregnancy.
- You're comfortable that the finished formulation is not FDA-approved.
Choose LillyDirect Zepbound vials if
- You want FDA-approved tirzepatide at the lowest possible cash price.
- You're comfortable drawing your own dose with a syringe.
- You can commit to refilling within the 45-day window every cycle.
Choose savings card + brand pen if
- You have commercial insurance with GLP-1 coverage and a qualifying diagnosis.
- You'd rather pay $25 a month than navigate compounding or vial logistics.
- You want the auto-injector pen form factor.
Red Flags When Buying Cheap Tirzepatide
The cheap end of the tirzepatide market includes both legitimate compounding pharmacies and outright scams. Cheap is fine. Cheap with no medical oversight is not.
Walk away if a provider
- Doesn't require any medical intake or consultation.
- Won't name the compounding pharmacy supplying the medication.
- Sells "research-only" tirzepatide vials for human use (this is the gray-market peptide world, not compounded medicine).
- Won't provide a Certificate of Analysis on request.
- Asks for crypto, Zelle, or wire transfer.
- Has no licensed prescriber listed by name and state.
- Quotes a price under $90 per month for tirzepatide (not realistic from a legitimate 503A pharmacy at current API costs).
What's Coming Mid-2026: TrumpRx and Medicare Bridge
Two pricing changes could move the floor again this year:
TrumpRx.gov launches mid-2026 as a federal portal consolidating manufacturer cash-pay programs. Initial reporting suggests Zepbound will be available through it at roughly $350 per month, slightly above LillyDirect's vial pricing but with the pen-injector form factor.
The Medicare GLP-1 Bridge Program begins July 2026 and is expected to bring qualifying Medicare Part D beneficiaries to a $50 monthly copay for Mounjaro for diabetes indications. Coverage for obesity-only indications (Zepbound) remains excluded from Medicare law and is not part of the bridge.
For non-tirzepatide routes and broader access options, see Ozempic, Wegovy and Zepbound without insurance, our GLP-1 prescription online walkthrough, and the best online GLP-1 program rankings.
More Ways to Lower Your Tirzepatide Cost
Beyond the ranked options above, these routes can cut the price further depending on your insurance, pharmacy, and tax-advantaged accounts.
Tirzepatide Cost With Insurance
Insurance coverage for tirzepatide varies enormously. Here's what you need to know about each major payer type:
Commercial (Employer-Sponsored) Insurance
As of 2026, approximately 25-43% of large employers cover GLP-1 drugs like tirzepatide for weight loss. Coverage rates are growing but are far from universal. When your plan does cover Zepbound or Mounjaro, you typically pay a copay or coinsurance of $100-$350+ per month depending on your tier.
Even with coverage, most plans require prior authorization (PA). PA criteria usually include:
- BMI ≥ 30, or BMI ≥ 27 with a weight-related comorbidity (diabetes, hypertension, sleep apnea)
- Documentation of at least one failed attempt at lifestyle modification
- No prior use of the same drug class within the past 12 months (some plans)
- Step therapy, trying a cheaper drug first (some plans)
If your commercial plan covers tirzepatide and you add the Zepbound Savings Card, your out-of-pocket cost can drop to as little as $25 per fill (up to a 3-month supply, $1,300 annual cap, commercially insured patients only).
Medicare
Traditional Medicare Part D does not currently cover tirzepatide for weight loss alone. However, Medicare may cover it for FDA-approved indications like type 2 diabetes (via Mounjaro) or obstructive sleep apnea (via Zepbound, on select Part D plans). A broader Medicare coverage expansion is expected to begin rolling out in January 2027, but participation will vary by plan and state. If you have Medicare and need tirzepatide for weight loss in 2026, expect to use LillyDirect self-pay pricing.
Medicaid
Medicaid coverage is state-by-state. All states cover Mounjaro for type 2 diabetes. Coverage for obesity varies widely, some states include GLP-1s for weight loss, others exclude them entirely. Medicaid beneficiaries are not eligible for Eli Lilly's savings card programs. Check your state's Medicaid formulary directly.
United Healthcare, Cigna, Aetna, BCBS
Major commercial insurers cover tirzepatide at varying tiers. United Healthcare (UHC) typically places Zepbound on Tier 3 or Tier 4 specialty, requiring prior auth. Cigna, Aetna, and BCBS plans differ by product line, employer, ACA marketplace, or self-funded, so there's no single answer. Always call your plan's Member Services or run a real-time formulary check before assuming coverage.
VA and TRICARE
VA formulary coverage for GLP-1s for weight loss is limited and varies by facility. TRICARE coverage similarly is not consistent. Neither VA nor TRICARE patients are eligible for Eli Lilly's savings card programs.
GoodRx Coupon Guide for Tirzepatide
GoodRx lists tirzepatide (Mounjaro and Zepbound) and can show discounted prices at retail pharmacies. However, in 2026, the savings from GoodRx on tirzepatide are modest compared to LillyDirect or compounded options.
Typical GoodRx prices for tirzepatide at retail pharmacies range from $950-$1,050/month, roughly 5-10% below the official list price. These savings are real but minor when LillyDirect offers the same drug for $299-$449/month.
When does GoodRx make sense for tirzepatide?
- You have commercial insurance but the plan's copay is higher than GoodRx (rare but possible)
- You need a prefilled pen rather than a vial (LillyDirect only offers vials)
- You're picking up from a local pharmacy and don't want to wait for direct shipping
Note: You cannot use GoodRx and insurance together. Using a coupon means you're paying out of pocket, and that fill will not count toward your insurance deductible.
Tirzepatide at Costco Pharmacy: Is It Actually Cheaper?
Costco Pharmacy is known for competitive pricing on many medications, and tirzepatide is no exception, relatively speaking. Costco's cash price for Mounjaro or Zepbound typically runs $900-$1,059 per month, which is modestly below the standard retail list price at CVS or Walgreens.
However, Costco's tirzepatide savings are minimal compared to LillyDirect ($299-$449/month). Costco pharmacy does not require a Costco membership to use the pharmacy (in most states), so it's accessible to non-members.
When Costco makes sense for tirzepatide:
- You need prefilled pens rather than vials (LillyDirect only offers vials)
- Your insurance covers tirzepatide and Costco is an in-network pharmacy
- You live near a Costco and want same-day pickup
You can check Costco Pharmacy's current tirzepatide price without a membership by calling your local Costco pharmacy directly.
FSA and HSA Eligibility for Tirzepatide
Good news: tirzepatide prescribed by a physician is generally considered a qualified medical expense for both Flexible Spending Accounts (FSA) and Health Savings Accounts (HSA). This means you can use pre-tax dollars to pay for your tirzepatide prescription, reducing your effective out-of-pocket cost by your marginal tax rate.
For example, if you're in the 22% federal tax bracket and paying $300/month for tirzepatide, using HSA funds saves you approximately $66/month ($792/year) in taxes.
FSA/HSA eligibility requirements for tirzepatide:
- Must be a valid prescription from a licensed provider
- Must be prescribed for an eligible medical condition (diabetes, obesity, sleep apnea)
- LillyDirect self-pay vials with a prescription: FSA/HSA eligible
- Telehealth consultation fees: often FSA/HSA eligible if for diagnosis or treatment
- Research peptides: NOT FSA/HSA eligible (not approved for human use)
Keep your prescription records and receipts. If your FSA/HSA administrator questions the eligibility, a letter of medical necessity (LMN) from your provider will resolve it. Many FSA/HSA accounts now include debit cards that can be used directly at pharmacies.
Generic Tirzepatide: When Will It Be Available?
Generic tirzepatide is not available in 2026, and it won't be for many years. Eli Lilly holds extensive patent protection on tirzepatide's molecular structure, formulation, and manufacturing processes. The key patents are expected to expire around 2036, meaning generic competition is roughly a decade away.
Here's the current generic tirzepatide timeline:
- 2026: No generics; brand-name only (Mounjaro, Zepbound)
- 2027-2035: Eli Lilly's patent protection in force; no generic entry expected
- ~2036+: First potential generic tirzepatide applications to FDA; actual availability depends on litigation, Paragraph IV challenges, and market dynamics
The FDA has approved a biosimilar pathway for biologics, but tirzepatide is a small synthetic peptide rather than a large-molecule biologic, meaning the generic pathway (ANDA) applies rather than the biosimilar pathway (BLA). This generally means lower development costs for generic manufacturers once patents expire.
Until generics arrive, LillyDirect self-pay pricing and compounded options (where legally available) remain the most accessible affordable routes.
Hims, Hers, and Ro: Telehealth Tirzepatide Pricing
Several telehealth platforms offer compounded tirzepatide at lower prices than the brand-name alternatives. As of early 2026, pricing and availability vary significantly by platform due to shifting FDA regulations on compounding (see next section).
Hers (forhers.com)
Hers has offered compounded tirzepatide for weight loss through an affiliated online prescribing service. Prices have ranged from approximately $199-$299/month for compounded tirzepatide injections, including the telehealth consultation fee. Check the Hers website for current pricing as this changes frequently with regulatory updates.
Hims (forhims.com)
Hims similarly offers access to compounded GLP-1 medications including tirzepatide through its telehealth platform. Pricing is typically in the $249-$399/month range, bundled with provider visits and ongoing monitoring. Hims also offers a subscription model that may reduce per-month cost for longer commitments.
Ro (ro.co)
Ro's Body program provides compounded tirzepatide and semaglutide through its Body program. Pricing is typically $299-$399/month for tirzepatide, with a required telehealth consultation. Ro has been vocal about transparency and includes lab work requirements as part of its program.
What to watch for: Telehealth platform prices often bundle in the cost of provider visits, follow-up care, and messaging, not just the medication. Ask for an itemized breakdown so you can compare apples-to-apples with LillyDirect.
Frequently Asked Questions
The Bottom Line
If you have commercial insurance and a qualifying diagnosis, the $25 savings card route wins. If you don't, compounded tirzepatide at $125 to $349 a month is the cheapest legal floor and the LillyDirect Zepbound vial at $299 is the cheapest FDA-approved cash option. Brand-name pen retail at $1,000+ is the worst value in the market in 2026 and almost nobody actually pays it.
Related: Tirzepatide Cost: Prices, Insurance & Cheapest Options · Tirzepatide Cost Without Insurance · Cheapest GLP-1 in 2026 · Compounded Tirzepatide Guide · GLP-1 Side Effects Compared
References
- Drugs@FDA: Zepbound (tirzepatide) approval record - FDA application data confirming Zepbound is FDA-approved tirzepatide for weight management.
- Drugs@FDA: Mounjaro (tirzepatide) approval record - FDA application data confirming Mounjaro is FDA-approved tirzepatide for Type 2 diabetes.
- FDA: Compounding and the FDA, Questions and Answers - Explains 503A versus 503B compounding rules that govern compounded tirzepatide.
- FDA: Medications Containing Semaglutide and Safety of Compounded GLP-1 Drugs - FDA guidance on the risks of unapproved and compounded GLP-1 products.
- SURMOUNT-1 trial (NEJM via PubMed) - Tirzepatide produced up to 20.9% body-weight reduction at 72 weeks.
- STEP-1 trial (NEJM via PubMed) - Semaglutide produced about 14.9% body-weight reduction, the comparison benchmark for tirzepatide.
- MedlinePlus: Tirzepatide Injection drug information - NIH consumer drug monograph covering dosing, use, and warnings.
- Medicare.gov: Part D Drug Coverage - Confirms Medicare prescription drug coverage rules relevant to GLP-1 access and the obesity-indication exclusion.